Imugene Ltd has released a press release.
$11.1 Million Placement Completed to Advance azer-cel
Earlier from Imugene
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- First Complete Response in Concurrent BTKi azer-cel Cohort
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Patient in BTKi Combination Cohort of azer-cel study